Treatment of Posttransplantation Recurrent Glomerulonephritis: IgA Nephropathy, Membranous Nephropathy, Membranoproliferative Glomerulonephritis.
10.4285/jkstn.2011.25.2.81
- Author:
Hyun Chul CHUNG
1
;
Jongha PARK
;
Jong Soo LEE
Author Information
1. Division of Nephrology, Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea. jslee@uuh.ulsan.kr
- Publication Type:Review ; Clinical Trial
- Keywords:
Kidney transplantation;
IgA nephropathy;
Membranous nephropathy;
Membranoproliferative glomerulonephritis;
Rituximab
- MeSH:
Antibodies, Monoclonal, Murine-Derived;
Glomerulonephritis;
Glomerulonephritis, IGA;
Glomerulonephritis, Membranoproliferative;
Glomerulonephritis, Membranous;
Humans;
Immunoglobulin A;
Incidence;
Kidney Transplantation;
Recurrence;
Rejection (Psychology);
Rituximab;
Transplantation, Homologous;
Transplants
- From:The Journal of the Korean Society for Transplantation
2011;25(2):81-86
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
As the clinical outcomes improve in kidney transplantation, largely because of the prevention of loss due to acute rejection, the incidence of allograft loss due to recurrent glomerulonephritis have become more important. Actually recurrent glomerulonephritis is the third most common cause of graft failure, ranking only behind immunologic rejection and death with a functioning graft. Preventive and therapeutic treatment strategies are necessary for those patients at risk. Current newer immunosuppressive protocols over the past 10 years have not affected the rate of disease recurrence or graft loss. In a certain recurrent glomerulitis, for example membranous nephropathy, there is emerging evidence that rituximab may be efficacious; however, larger clinical trials are warranted.
